Tykerb and Metastatic neoplasm - a phase IV clinical study of FDA data

Summary:

Metastatic neoplasm is reported as a side effect among people who take Tykerb (lapatinib ditosylate), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Xeloda, and have Neoplasm malignant.

The phase IV clinical study analyzes which people have Metastatic neoplasm when taking Tykerb. It is created by eHealthMe based on reports of 12,186 people who have side effects when taking Tykerb from the FDA, and is updated regularly.

What is Tykerb?

Tykerb has active ingredients of lapatinib ditosylate. It is often used in breast cancer. eHealthMe is studying from 12,231 Tykerb users. Check the latest studies of Tykerb.

What is Metastatic neoplasm?

Metastatic neoplasm (spreadable cancer tumour) is found to be associated with 604 drugs and 516 conditions by eHealthMe. Check the latest studies of Metastatic neoplasm.

On Jul, 13, 2026

12,186 people reported to have side effects when taking Tykerb.
Among them, 29 people (0.24%) have Metastatic neoplasm.

Among these 29 people:

How long have people been on Tykerb when they have Metastatic neoplasm? *

What is the gender of people who have Metastatic neoplasm when taking Tykerb? *

female: 89.66 %
male: 10.34 %

What is the age of people who have Metastatic neoplasm when taking Tykerb? *

What are other drugs people take besides Tykerb? *

What are other side effects people have besides Metastatic neoplasm? *

Disease Progression: 10 people, 34.48%
Diarrhea: 8 people, 27.59%
Drug Ineffective: 5 people, 17.24%
Nausea (feeling of having an urge to vomit): 4 people, 13.79%
Onychalgia (nail biting): 3 people, 10.34%
Gastrointestinal Bacterial Infection (infection of the stomach and intestines caused by bacteria): 3 people, 10.34%
Onychomadesis (a periodic idiopathic shedding of the nails): 3 people, 10.34%
Nausea And Vomiting: 3 people, 10.34%
Pain In Extremity: 3 people, 10.34%
Nail Discoloration: 3 people, 10.34%

What are the existing conditions these people have? *

Neoplasm Malignant (cancer tumour): 3 people, 10.34%
Metastases To Pleura (cancer spreads to pleura): 2 people, 6.90%
Pain: 1 person, 3.45%
Osteoporosis (bones weak and more likely to break): 1 person, 3.45%
Diabetes: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Tykerb and have Metastatic neoplasm?

- Check whether Metastatic neoplasm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tykerb:

Tykerb (12,231 reports)

Browse all side effects of Tykerb:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastatic neoplasm:

Metastatic neoplasm (604 drugs)

Browse all the conditions that are associated with Metastatic neoplasm:

Metastatic neoplasm (516 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lapatinib ditosylate (the active ingredients of Tykerb) and Tykerb (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.